Filing Analysis
Elutia Inc. has completed the sale of its SimpliDerm Business (Women's Health segment) to Cellution Biologics Inc. for an initial $7.7 million, with potential contingent payments of up to $3 million. The transaction includes a five-year non-compete agreement and a six-month transition services agreement.
🚩 Red Flags
- Divestiture of a primary business segment (Women's Health) suggests a significant shift in corporate strategy or a need for liquidity.
- Contingent payments and inventory adjustments introduce uncertainty regarding the final total cash proceeds.
📋 Key Facts
- Completed sale of SimpliDerm Business assets to Cellution Biologics Inc. on August 17, 2026.
- Upfront cash consideration of $7.7 million received at closing.
- Potential for up to $3 million in additional contingent payments over 18 months based on technology transfer and commercial milestones.
- Purchase price subject to post-closing inventory valuation adjustments.
- Company entered into a 5-year non-competition agreement regarding human acellular dermis products.
- Company will provide transition services for up to six months.
- Amended Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. to release liens on the sold assets.
Elutia Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of earnings and does not contain substantive changes to corporate structure or material agreements.
📋 Key Facts
- Reported date: August 13, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Elutia Inc. received a notice from Nasdaq stating that its common stock has been below the $1.00 minimum bid price for 30 consecutive business days. The company has a compliance period until February 2, 2027, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for a mandatory reverse stock split to cure deficiency
- Failure to maintain minimum bid price requirement
📋 Key Facts
- Nasdaq issued a deficiency notice on August 6, 2026.
- The stock failed the minimum bid price requirement (Rule 5550(a)(2)) by trading below $1.00 for 30 consecutive business days.
- A compliance period has been granted until February 2, 2027.
- To regain compliance during the second 180-day extension window (if applicable), the company may need to effect a reverse stock split.
Elutia Inc. has entered into an agreement to sell substantially all assets of its Women’s Health segment, specifically the SimpliDerm® brand, to Cellution Biologics Inc. for a total potential consideration of up to $11 million.
🚩 Red Flags
- Significant divestiture of a core segment (Women's Health) which may signal a pivot or liquidity need.
- High proportion of consideration is contingent ($3M out of $11M, or ~27%) based on milestones and sales targets.
- The company is selling 'substantially all assets' of a major segment, indicating a potential narrowing of business scope.
📋 Key Facts
- Agreement dated July 16, 2026; Closing expected in H2 2026.
- Total potential purchase price: $11 million ($8M base cash + $2M technology/manufacturing milestones + $1M earn-outs).
- The sale includes substantially all assets of the SimpliDerm® business (human acellular dermis products for breast reconstruction).
- Elutia is subject to a 5-year non-compete and non-solicitation agreement regarding the SimpliDerm business.
- Includes a transition services agreement where Elutia will support Cellution Biologics post-closing.
Elutia Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Shareholders approved the election of directors, the ratification of PwC as auditors, and an amendment to the 2020 Incentive Award Plan.
📋 Key Facts
- Stockholders approved the First Amendment to the 2020 Incentive Award Plan, increasing authorized shares for awards by 3,000,000 Class A common shares.
- The 2020 Plan's termination date and annual share increase period were extended to January 1, 2036.
- David Colpman and Kevin Rakin were elected as Class III directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Stockholders voted for an annual frequency for future advisory 'say-on-pay' votes.
- Quorum was established with 34,041,545 shares present or represented by proxy (approx. 77.0% of outstanding Class A common stock).
Elutia Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed financial results is included as Exhibit 99.1.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Elutia Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing under Item 2.02.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2025.
- Press release date: March 11, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- The report was signed by Matthew Ferguson, Chief Financial Officer.
Elutia Inc. adopted the 2026 Inducement Award Plan on March 3, 2026, reserving 2,000,000 shares of Class A common stock to attract new employees. The plan utilizes Nasdaq's inducement grant exception, allowing the company to issue equity to new hires without seeking prior shareholder approval.
📋 Key Facts
- The 2026 Inducement Award Plan was adopted by the Board on March 3, 2026.
- A maximum of 2,000,000 shares of Class A common stock are reserved for issuance under the plan.
- Grants are restricted to individuals not previously employees or directors, or those returning after a bona fide interruption, per Nasdaq Listing Rule 5635(c)(4).
- The plan allows for various equity awards including stock options, SARs, restricted stock, and RSUs.
- The Compensation Committee will serve as the Administrator with broad authority over award terms and potential repricing.
Elutia Inc. has regained compliance with Nasdaq's minimum bid price and market value of listed securities (MVLS) requirements, resolving previous deficiency notices from late 2025.
🚩 Red Flags
- Recent history of non-compliance with multiple Nasdaq listing standards including bid price, MVLS, and shareholder equity/net income standards.
- The company's market capitalization recently dipped below the $35 million threshold, indicating significant valuation volatility.
📋 Key Facts
- The company regained compliance with the $1.00 minimum bid price requirement on March 2, 2026, after maintaining the price for 10 consecutive business days from February 13 to February 27, 2026.
- The company regained compliance with the $35 million MVLS requirement on February 5, 2026, after maintaining the value for 11 consecutive business days from January 21 to February 4, 2026.
- The initial bid price deficiency notice was received on November 7, 2025.
- The initial MVLS deficiency notice was received on December 23, 2025, which also noted failures to meet shareholder equity or net income standards.
Elutia Inc. issued an 8-K to announce the release of its preliminary results for the fourth quarter ended December 31, 2025. The filing notes that these figures are subject to standard year-end audit and closing procedures.
📋 Key Facts
- Preliminary Q4 2025 financial results announced on January 12, 2026.
- Results are preliminary and subject to normal year-end accounting closing and audit procedures.
- The filing includes a press release as Exhibit 99.1.
Elutia Inc. received a notice from Nasdaq for failing to meet the Minimum Market Value of Listed Securities (MVLS) requirement, having fallen below $35 million for 30 consecutive business days. The company is also currently out of compliance with the $1.00 minimum bid price rule.
🚩 Red Flags
- Delisting notice regarding Minimum Market Value of Listed Securities (MVLS).
- Existing non-compliance with the $1.00 minimum bid price rule.
- Potential requirement for a reverse stock split to cure bid price deficiency.
- Failure to meet additional Nasdaq requirements relating to shareholder equity or net income.
📋 Key Facts
- Received Nasdaq notice on December 23, 2025, regarding violation of Nasdaq Listing Rule 5550(b)(2) (MVLS Requirement).
- Company's MVLS was below $35 million for the previous 30 consecutive business days.
- The company is already out of compliance with the Bid Price Rule ($1.00 minimum bid price) as of November 7, 2025.
- Deadline to regain MVLS compliance: June 22, 2026 (180-day period).
- Deadline to regain Bid Price compliance: May 6, 2026 (with potential for a second 180-day extension if other requirements are met).
Elutia Inc. received a notice from Nasdaq stating that its common stock has been below the $1.00 minimum bid price for 30 consecutive business days. The company has a compliance period until May 6, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Failure to meet Nasdaq's minimum bid price requirement ($1.00).
- Potential for delisting if compliance is not met by May 2026.
- Explicit mention of a potential reverse stock split as a cure mechanism.
📋 Key Facts
- Received notice from Nasdaq on November 7, 2025.
- Closing bid price was below $1.00 for the last 30 consecutive business days.
- Compliance period granted until May 6, 2026 (180 calendar days).
- To regain compliance via an additional extension, a reverse stock split may be required.
Elutia Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the earnings press release issued on November 6, 2025.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
Elutia Inc. announced significant changes to its Board of Directors, including the election of Guido Neels and the simultaneous resignation of two directors, Maybelle Jordan and W. Matthew Zuga.
🚩 Red Flags
- Multiple director departures (two directors resigning simultaneously) within a single filing period.
📋 Key Facts
- Guido Neels elected to the Board and appointed to the Audit Committee effective October 9, 2025.
- Mr. Neels granted an option to purchase 171,916 shares of Class A Common Stock at $0.88 per share, vesting over three years.
- Maybelle Jordan resigned from the Board effective October 8, 2025.
- W. Matthew Zuga resigned from the Board effective October 8, 2025.
- The company stated that the resignations were not due to any disagreement regarding operations, policies, or practices.
Elutia Inc. has completed the sale of its Cardiac Implantable Electronic Device (CIED) Business to Boston Scientific Corporation and Cardiac Pacemakers, Inc. for a total consideration involving $80.3 million in proceeds, with $8 million held in escrow.
🚩 Red Flags
- Significant portion of sale proceeds ($8M) is locked in escrow for 12 months, limiting immediate liquidity.
- The company has divested its primary business segment (Device Protection), leaving the future core operations undefined in this filing.
📋 Key Facts
- Completed sale of CIED Business assets on October 1, 2025.
- Total cash paid to Sellers was $80.3 million (subject to inventory adjustments).
- $8 million of the purchase price is held in escrow for 12 months as an indemnification fund.
- Elutia used approximately $27.8 million of sale proceeds to pay off and terminate its Credit Agreement with SWK Funding LLC.
- Ligand Pharmaceuticals released its security interest in CIED Assets following a $1.1 million payment of accrued royalties by Elutia Med.
- Sellers entered into a 5-year non-competition agreement and a 12-30 month transition services agreement.
Elutia Inc. has entered into an agreement to sell substantially all assets of its Cardiac Implantable Electronic Device (CIED) Business to Boston Scientific Corporation and Cardiac Pacemakers Inc. for up to $88 million in cash.
🚩 Red Flags
- Going concern language detected in forward-looking statements ('risk regarding our ability to continue as a going concern').
- Significant shift in business model: The company is divesting its primary device segment to focus on drug-eluting biomatrix solutions.
- Legal/Financial risks mentioned: Potential impact of lawsuits related to FiberCel and VBM, and significant indebtedness including Revenue Interest Obligations.
📋 Key Facts
- Total transaction value: Up to $88 million in cash ($80M at closing, $8M held in escrow for 12 months).
- Buyers: Boston Scientific Corporation (BSC) and Cardiac Pacemakers Inc. (CPI).
- Assets included: Substantially all assets related to the CIED Business (CanGaroo®, CanGaroo® RM, EluPro™, and CIED envelope products).
- Expected closing date: Fourth quarter of 2025.
- Non-compete clause: Elutia is subject to a five-year non-competition restriction regarding the CIED Business lines.
Elutia Inc. entered into a Fifth Amendment to its $25.0 million senior secured term loan with SWK Funding LLC on August 15, 2025. The amendment allows for the capitalization of accrued interest and various amendment fees into the unpaid principal balance.
🚩 Red Flags
- Capitalization of interest and fees into principal (PIK-like mechanism) often indicates a company is struggling to meet immediate cash obligations for debt service.
- Multiple amendments to credit facilities suggest ongoing restructuring or liquidity management issues.
📋 Key Facts
- Entered into Fifth Amendment to Credit Agreement dated August 14, 2025.
- The original SWK Facility is a $25.0 million senior secured term loan.
- Accrued and unpaid interest due in August 2025 will be capitalized into the principal balance.
- A $50,000 amendment fee from June 30, 2025, will be capitalized.
- An additional $10,000 amendment fee related to this current Amendment will be capitalized.
Elutia Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Elutia Inc. held its annual meeting of stockholders on May 29, 2025. The company successfully elected two Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual meeting held on May 29, 2025.
- Quorum reached with 29,585,703 shares present (approx. 80.9% of Class A common stock outstanding).
- Brigid A. Makes and C. Randal Mills, Ph.D. were elected to the Board of Directors as Class II directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
Elutia Inc. has entered into significant agreements to settle outstanding royalty obligations and amend its credit facility, primarily through the issuance of equity rather than cash. The company is converting $2.2 million in royalties to Ligand Pharmaceuticals into 1,105,528 shares and issuing 50,000 shares to lenders as consideration for a debt amendment.
🚩 Red Flags
- Significant equity dilution: Converting cash obligations to equity suggests liquidity constraints.
- Debt restructuring/PIK interest: Allowing 100% of May 2025 interest to be paid in kind is a classic sign of cash preservation needs.
- Multiple material items (Royalty settlement, Debt amendment, and Earnings release) in a single filing.
📋 Key Facts
- Settled $2.2 million in unpaid/accrued royalty obligations to Ligand via issuance of 1,105,528 Class A Common Shares at $1.99 per share.
- Amended SWK Facility (senior secured term loan of $25M) allowing for 100% PIK (payment-in-kind) on May 2025 interest obligations.
- Issued 50,000 Class A Common Shares to SWK Facility lenders as consideration for the amendment.
- SWK Amendment allows for a potential $5.0 million new term loan advance at lender discretion.
- Fixed minimum consolidated unencumbered liquid assets covenant at $8.0 million.
Elutia Inc. has terminated its exclusive distribution agreement with LeMaitre Vascular, Inc. for several product lines in the United States. The company intends to transition to a direct distribution model for these products.
🚩 Red Flags
- Transitioning from a distributor model to direct distribution can lead to significant increases in operating expenses (logistics, sales force, inventory management) and potential short-term revenue disruption during the transition.
📋 Key Facts
- Termination date of Distribution Agreement: April 30, 2025.
- Agreement was originally dated April 20, 2023.
- Products affected: ProxiCor® PC, ProxiCor® CTR, Tyke®, and VasCure®.
- The company will transition to direct distribution of these products in the U.S.
- No early termination penalties were incurred from this termination.
Elutia Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the release of their earnings press release.
📋 Key Facts
- Report date: March 6, 2025
- Reporting period: Fourth quarter and full year ended December 31, 2024
- The company is an emerging growth company
- Results were released via press release (Exhibit 99.1)
Elutia Inc. has completed a registered direct offering of 5,520,000 shares and 480,000 prefunded warrants at $2.50 per share, raising approximately $15.0 million in gross proceeds. The funds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Issuance of prefunded warrants with near-zero exercise prices can lead to significant future dilution.
- The company is an 'emerging growth company,' which often implies a need for frequent capital raises to sustain operations.
📋 Key Facts
- Offering size: 5,520,000 Class A common shares and up to 480,000 prefunded warrants.
- Pricing: $2.50 per share; Prefunded Warrants priced at $2.499 with an exercise price of $0.001.
- Gross proceeds: Approximately $15.0 million (before fees and expenses).
- Placement Agent: Lake Street Capital Markets, LLC received a 6.0% cash fee plus expenses.
- Lock-up period: Directors and officers are subject to a 90-day lock-up following the closing on February 4, 2025.
- Use of proceeds: Working capital and general corporate purposes.
Elutia Inc. released preliminary net sales estimates for the fiscal year ended December 31, 2024. The company expects total net sales of approximately $24.4 million, representing a slight decrease of 1% compared to the previous year.
🚩 Red Flags
- Significant decline in Cardiovascular segment revenue (-42%).
- Forward-looking statements explicitly mention risks regarding 'ability to continue as a going concern' and potential material adverse consequences from lawsuits related to recalled FiberCel products.
📋 Key Facts
- Preliminary 2024 Total Net Sales: $24,375,000 (vs. $24,745,000 in 2023).
- Device protection sales grew 5% to $9.9 million.
- Women’s health sales increased 12% to $11.6 million.
- Cardiovascular sales declined 42% to $2.9 million.
- PricewaterhouseCoopers LLP has not audited or reviewed these preliminary estimates.
Elutia Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing was made on November 14, 2024.
- The report pertains to the third quarter (Q3) ended September 30, 2024.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Elutia Inc. entered into a Third Amendment to its $25.0 million senior secured term loan with SWK Funding LLC on September 30, 2024. The amendment primarily serves to defer principal repayments and interest-in-kind options by one year.
🚩 Red Flags
- Debt restructuring/extension suggests liquidity constraints or a need for more time to meet repayment obligations.
- Increased exit fee indicates higher costs associated with refinancing or terminating the debt.
- The deferral of principal payments is often a defensive measure used by companies facing cash flow challenges.
📋 Key Facts
- Entered into Third Amendment to Credit Agreement on September 30, 2024.
- The SWK Facility is a $25.0 million senior secured term loan.
- Principal repayment commencement deferred from November 15, 2024, to November 15, 2025.
- Extension of the option to pay interest-in-kind (PIK) from November 15, 2024, to November 15, 2025.
- Exit fee upon termination increased from $62,500 + 6.5% to $112,500 + 6.5% of the aggregate Term Loan funded.
Elutia Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2024.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing includes a press release regarding results of operations and financial condition (Exhibit 99.1).
Elutia Inc. completed a registered direct offering of 3,175,000 shares of Class A common stock and 725,000 prefunded warrants at $3.40 per share. The offering raised approximately $13.26 million in gross proceeds to be used for working capital and general corporate purposes.
🚩 Red Flags
- Issuance of prefunded warrants with near-zero exercise prices ($0.001) can lead to significant future dilution when exercised.
- The offering is a registered direct offering, often used by micro-cap companies to raise capital quickly.
📋 Key Facts
- Offering closed on June 18, 2024.
- Total shares offered: 3,175,000 Class A Common Stock; 725,000 Prefunded Warrants.
- Public offering price per share: $3.40 for common stock and $3.399 for prefunded warrants.
- Gross proceeds: approximately $13.26 million (before fees/expenses).
- Placement Agent fee: 7.0% of gross proceeds plus expenses.
- Warrants are immediately exercisable at a nominal price of $0.001 per share.
- Includes a 90-day lock-up agreement for directors and officers.
Elutia Inc. announced that the FDA has cleared its antibiotic-eluting bioenvelope, EluPro® (CanGaroo®RM), via a 510(k) premarket notification, determining it is substantially equivalent to existing devices.
📋 Key Facts
- FDA clearance received for EluPro® antibacterial envelope device on June 14, 2024.
- The FDA determined 'substantial equivalence' under Section 510(k) of the Federal Food, Drug and Cosmetic Act.
- The device may now be marketed subject to general controls provisions of the Act.
Elutia Inc. held its annual meeting of stockholders on June 6, 2024. The company successfully elected two Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual meeting held on June 6, 2024.
- Quorum reached with 12,975,682 shares present (approx. 64.8% of Class A common stock outstanding).
- Maybelle Jordan and W. Matthew Zuga were elected to the Board of Directors as Class I directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
Elutia Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings release issued on May 9, 2024.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The company is an emerging growth company.
- Results were announced via a press release (Exhibit 99.1).
Elutia Inc. entered into a Second Amendment to its existing Credit Agreement with SWK Funding LLC on March 27, 2024. The amendment modifies the minimum aggregate revenue covenant required under the facility.
🚩 Red Flags
- Modification of financial covenants often indicates a need for more flexibility due to performance pressure or risk of breach.
- The requirement for $20M in trailing twelve-month revenue establishes a high bar for the company's commercial scale.
📋 Key Facts
- Amendment date: March 27, 2024
- Parties involved: Elutia Inc. (Borrower), SWK Funding LLC (Agent), and various Lenders
- Modification: Adjusted minimum aggregate revenue covenant for the trailing twelve-month period.
- New Covenant Requirement: Minimum Aggregate Revenue must be equal to or greater than $20,000,000 as of the last business day of each fiscal quarter starting Q1 2024.
Elutia Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of the earnings press release issued on March 7, 2024.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing includes a press release as Exhibit 99.1
- Company is an emerging growth company
Elutia Inc. has implemented significant compensation restructuring, including repricing 'underwater' stock options for employees and granting substantial new equity incentives to the CEO, CFO, and CSO. These actions are tied to both share price milestones and FDA clearance of the company's CanGaroo®RM antibiotic-eluting biologic envelope.
🚩 Red Flags
- Significant dilution potential due to large new equity grants (over 2 million total shares across various incentive tiers).
- Repricing of options is a classic sign of extreme stock price depression, as the filing notes nearly all employee options were 'underwater'.
- Heavy reliance on binary regulatory events (FDA clearance) for executive compensation vesting.
📋 Key Facts
- CEO C. Randal Mills repriced existing stock options/RSUs by lowering vesting thresholds from $12.50-$37.00 down to $6.00-$18.00 per share.
- New CEO incentives include 650,000 stock options and 650,000 RSUs with an exercise price of $3.61.
- CFO Matthew Ferguson and CSO Michelle L. Williams were each granted 200,000 stock options and 200,000 RSUs at a $3.61 exercise price.
- A portion of executive incentives (Clearance Criteria RSUs/Options) is tied to FDA clearance of the CanGaroo®RM product.
- The company repriced 144,427 shares for non-executive employees from original prices as high as $17.00 down to $3.61.
Elutia Inc. has amended its existing royalty agreement with Ligand Pharmaceuticals, significantly increasing minimum annual and quarterly payment obligations through 2027. The amendment also includes a lump-sum settlement for past-due royalties from 2023.
🚩 Red Flags
- Significant increase in fixed cash outflows (Minimum Annual Royalty up ~60%).
- Settlement of past-due obligations ($3.0M for 2023 royalties) suggests potential liquidity or cash flow strain.
- The obligation is secured by a lien on the subsidiary's assets, reducing asset flexibility.
📋 Key Facts
- Amendment No. 1 to Royalty Agreement entered into on January 10, 2024, with Ligand Pharmaceuticals Incorporated.
- Minimum Annual Royalty increased from $2.75 million to $4.4 million for 2024 and subsequent years through May 31, 2027.
- Minimum Quarterly Payments increased from ~$0.7 million to $1.1 million starting October 1, 2023.
- Elutia Med LLC agreed to pay $3.0 million to satisfy all royalty obligations for the first three fiscal quarters of 2023 (50% by Jan 20, 2024; 50% by April 10, 2024).
- Ligand waived a $5.0 million milestone payment that was due in Q2 2023.
- Obligations are secured by a lien on the assets of Elutia Med LLC and guaranteed by Elutia Inc.
Elutia Inc. has regained compliance with Nasdaq's Board Independence Rule (Rule 5605(b)(1)). This follows the company previously regaining compliance with the Market Value Standard, effectively resolving previous delisting threats.
🚩 Red Flags
- Historical non-compliance with Nasdaq listing rules regarding board independence and market value standards.
📋 Key Facts
- On January 9, 2024, Nasdaq confirmed Elutia Inc. regained compliance with Listing Rule 5605(b)(1) (Board Independence Rule).
- Compliance was achieved by confirming a majority of the Board of Directors are 'independent' per Listing Rule 5605(a)(2).
- The company had previously notified Nasdaq on December 5, 2023, that it was non-compliant due to having only three independent directors out of six.
- The scheduled hearing with the Nasdaq Hearings Panel to appeal prior delisting determinations has been canceled.
- Class A common stock (ELUT) remains listed on the Nasdaq Capital Market.